Hdacs/mtor inhibitor synergizes with pyrotinib in her2-positive pancreatic cancer through degradation of mutant p53

HIGHLIGHTS

• who: Tiebo Mao from the The study was conducted in accordance with International Ethical Guidelines for Biomedical Research Involving Human Subjects (CIOMS)The study was approved by the Research Ethics Committee of Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University (Shanghai, P.R. China). Written informed consent was provided to all the patients before enrollment. The patient cohort of human pancreatic tissue array containing , PDAC specimens and corresponding noncancerous tissues were also obtained from Ren Ji Hospital (Shanghai Jiao Tong University School of Medicine, Shanghai, P.R. China) from January , to January, . Patients had not . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.